GSK terminated development of camlipixant for refractory chronic cough (RCC). The decision follows mixed outcomes from the CALM-1 and CALM-2 Phase 3 trials.
GSK originally acquired the drug through a $2 billion buyout of Bellus Health. The company previously viewed the treatment as a key driver for future revenue.
The CALM-1 study met its primary goal of reducing cough frequency at 12 weeks. However, the CALM-2 trial failed to demonstrate statistically significant benefits at 24 weeks.
GSK determined the drug's efficacy was limited and unlikely to transform patient care. This failure impacts GSK's late-stage pipeline for conditions with limited treatment options.
Camlipixant maintained a favorable safety profile with side effects comparable to a placebo. GSK will continue a mid-stage trial of the drug for treating irritable bowel syndrome.